1123515-36-5 Usage
Uses
Used in Organic Synthesis:
(5-Bromo-pyrimidin-2-yl)-(4-methyl-3-nitro-phenyl)-amine is used as a building block for the synthesis of more complex organic molecules, leveraging its reactive functional groups and structural diversity to create novel compounds with potential applications in various fields.
Used in Medicinal Chemistry:
In the pharmaceutical industry, (5-Bromo-pyrimidin-2-yl)-(4-methyl-3-nitro-phenyl)-amine is used as a starting material or intermediate in the development of new drugs. Its unique structure may allow for the creation of molecules with specific biological activities, potentially leading to the discovery of new therapeutic agents.
Further research is required to fully explore the properties and potential applications of (5-Bromo-pyrimidin-2-yl)-(4-methyl-3-nitro-phenyl)-amine, as its complex structure and potential reactivity suggest a wide range of possibilities in both organic synthesis and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1123515-36-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,2,3,5,1 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1123515-36:
(9*1)+(8*1)+(7*2)+(6*3)+(5*5)+(4*1)+(3*5)+(2*3)+(1*6)=105
105 % 10 = 5
So 1123515-36-5 is a valid CAS Registry Number.
1123515-36-5Relevant academic research and scientific papers
5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
-
Page/Page column 55, (2009/04/25)
The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.
